Dr. Niels Krebsfaenger

Berufserfahrung von Niels Krebsfaenger

• Bis heute 3 Jahre und 11 Monate, seit Aug. 2020

  Executive Director, Global Pharmacovigilance

  Elanco / Bayer Animal Health

  Leading and overseeing all pharmacovigilance activities, budget and staff at Elanco Animal Health worldwide. Member of the R&D Leadership Team and Elanco Senior Management Team Key accomplishments: - Business continuity and compliance delivered during integration of Bayer Animal Health in Elanco while mitigating COVID-19 crisis.

• 2 Jahre und 7 Monate, Jan. 2018 - Juli 2020

  Head Regulatory Affairs & Drug Safety

  Bayer Animal Health GmbH

  Full responsibility for all regulatory affairs (RA) and pharmacovigilance (PV) activities at Bayer Animal Health Key accomplishments: - Successful integration of RA and PV: cost turnaround, improved metrics/KPIs, strong team engagement - Business continuity, compliance and innovation delivered while preparing for M&A process and mitigating COVID-19 crisis - ~300 new product registrations / line extensions worldwide every year

• 8 Monate, Mai 2017 - Dez. 2017

  Head Drug Safety

  Bayer Animal Health GmbH

• 7 Jahre und 10 Monate, Juli 2009 - Apr. 2017

  Head of Group 'Innovation & Services' (within 'Global Regulatory Affairs')

  Bayer Animal Health GmbH

  Full responsibility for regulatory affairs in global R&D project teams, global regulatory operations, label management, and regulatory intelligence Key accomplishments: - Deliver innovation to market by ~300 new product registrations / line extensions worldwide every year - Contribution to tripling pipeline value within 10 years - Increase efficiency and compliance by industry-leading end-to-end electronic workflow in regulatory affairs

• 5 Jahre und 3 Monate, Apr. 2004 - Juni 2009

  Preclinical Subteam Leader, Group Leader Toxicology

  Schwarz Pharma / UCB Pharma

  Key accomplishments: - Leading a group and project subteam through the Schwarz / UCB integration. - Definition of global non-clinical development strategies and leading non-clinical teams in global development projects and at agency meetings. One new global product to market: Vimpat® (lacosamide) - Evaluation and implementation of new non-clinical test guidelines and strategies (e.g. environmental risk assessment, abuse liability assessment, juvenile toxicity testing, ...)

• 3 Jahre und 2 Monate, Feb. 2001 - März 2004

  Co-Founder, Head ADME-Tox and R&D

  GenPharmTox BioTech AG

  Key accomplishments: - Break even. - Establishment and GLP (re)-certification of in vitro ADME-Tox and bioanalytical laboratories.

• 1 Jahr und 5 Monate, Sep. 1999 - Jan. 2001

  Toxicologist

  Boehringer Ingelheim